Stocks TelegraphStocks Telegraph
Stock Ideas

RYZB Company Profile and Key Details

NASDAQ : RYZB

RayzeBio, Inc. Common Stock

$62.49
0.01+0.02%
At Close 4:00 PM
Not Actively Trading

RYZB Stock Price Chart

Stock Price Today

RayzeBio, Inc. Common Stock (RYZB) stock surged +0.02%, trading at $62.49 on NASDAQ, up from the previous close of $62.48. The stock opened at $62.49, fluctuating between $62.48 and $62.50 in the recent session.

Stock Snapshot

62.48
Prev. Close
62.49
Open
3.75B
Market Cap
60.02M
Number of Shares
62.48
Day Low
62.5
Day High
-57.861111111111114
P/E Ratio
58.02%
Free Float in %
-1.08
EPS (TTM)
37.36
Book Value
-3.85
Cash Flow per Share
282.72K
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Mar 06, 202462.4962.4962.4962.490
Mar 05, 202462.4962.4962.4962.490
Mar 04, 202462.4962.4962.4962.490
Mar 01, 202462.4962.4962.4962.490
Feb 29, 202462.4962.4962.4962.490
Feb 28, 202462.4962.4962.4962.490
Feb 27, 202462.4962.4962.4962.490
Feb 26, 202462.4962.4962.4962.490
Feb 23, 202462.4962.5062.4862.49282.72K
Feb 22, 202462.4962.5162.4862.48161.42K
Feb 21, 202462.4862.5062.4862.48172.98K
Feb 20, 202462.4562.4962.4362.49457.49K
Feb 16, 202462.4462.4662.4262.43135.48K
Feb 15, 202462.4262.4462.4062.41168.25K
Feb 14, 202462.4262.4262.3962.42316.1K
Feb 13, 202462.4062.4262.3862.39452.62K
Feb 12, 202462.3862.4062.3862.39578.3K
Feb 09, 202462.2262.3662.2262.32315.34K
Feb 08, 202462.1862.3562.1362.27238.22K
Feb 07, 202462.1562.1662.1162.16180.63K

Contact Details

United States

Website: No DataContact: 0

About Company

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.

Company Information

Employees88
Beta0
Sales or RevenueN/A
5Y Sales Change%N/A
Fiscal Year EndsN/A
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current RayzeBio, Inc. Common Stock (RYZB) stock price?

RayzeBio, Inc. Common Stock (NASDAQ: RYZB) stock price is $62.49 in the last trading session. During the trading session, RYZB stock reached the peak price of $62.50 while $62.48 was the lowest point it dropped to. The percentage change in RYZB stock occurred in the recent session was 0.02% while the dollar amount for the price change in RYZB stock was $0.01.

RYZB's industry and sector of operation?

The NASDAQ listed RYZB is part of Biotechnology industry that operates in the broader Healthcare sector. RayzeBio, Inc. Common Stock designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RYZB?

No Data

How RYZB did perform over past 52-week?

RYZB's closing price is 248.13% higher than its 52-week low of $17.95 where as its distance from 52-week high of $62.51 is -0.03%.

How many employees does RYZB have?

Number of RYZB employees currently stands at 88.

Link for RYZB official website?

Official Website of RYZB is:

How do I contact RYZB?

RYZB could be contacted at phone 0 and can also be accessed through its website. RYZB operates from , , , United States.

How many shares of RYZB are traded daily?

RYZB stock volume for the day was 282.72K shares. The average number of RYZB shares traded daily for last 3 months was 745.49K.

What is the market cap of RYZB currently?

The market value of RYZB currently stands at $3.75B with its latest stock price at $62.49 and 60.02M of its shares outstanding.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph